Revolution Medicines, Inc. provided updates on the clinical safety and efficacy of its drug RMC-6236 for treating RAS-mutant pancreatic and lung cancers, reporting a 36% objective response rate in pancreatic cancer and a median progression-free survival of 8.8 months for KRAS G12X mutations, while also detailing safety data from various studies.